Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proteomic cancer classification with mass spectrometry data.

Jagath C Rajapakse1, Kai-Bo Duan, Wee Kiang Yeo

  • 1BioInformatics Research Centre, School of Computer Engineering, Nanyang Technological University, Singapore. asjagath@ntu.edu.sg

American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice
|October 4, 2005
PubMed
Summary

Cancer proteomics aims for clinical diagnostics using mass spectrometry (MS). A novel support vector machine-recursive feature elimination (SVM-RFE) method enhances cancer classification accuracy by selecting key protein biomarkers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

D3I-COMCF: Dissimilarity-driven dual-interaction via co-occurrence motifs and complementary fragments for drug-drug interaction prediction.

Neural networks : the official journal of the International Neural Network Society·2026
Same author

Integrating multimodal features with deep learning for protein solubility prediction.

Journal of cheminformatics·2026
Same author

LABMA: Latent-bottleneck attention-based multimodal architecture for integration of transcriptomics, proteomics, and MRI in neurodegeneration.

Computers in biology and medicine·2026
Same author

Encoding and Decoding of Brain Dynamic Functional Connectivity for ADHD Diagnosis.

IEEE journal of biomedical and health informatics·2026
Same author

Entropy-based byte patching transformer for self-supervised pretraining of SMILES data.

iScience·2026
Same author

Target-aware latent diffusion model for design of apoptosis-inducing anticancer peptides.

Computers in biology and medicine·2025

Area of Science:

  • Proteomics
  • Biomarker Discovery
  • Clinical Diagnostics

Background:

  • Cancer proteomics seeks to integrate proteomic technologies into clinical settings for disease classification and treatment evaluation.
  • Tumor-specific proteomic profiles offer insights into cancer development and potential therapeutic targets.
  • Key challenges include biological variability and wide dynamic ranges of biomarker concentrations, hindering diagnostic pattern identification.

Purpose of the Study:

  • To adapt mass spectrometry (MS) for high-throughput proteomic profiling in cancer classification.
  • To identify robust protein biomarkers for distinguishing between cancer and non-cancer states or different cancer stages.
  • To demonstrate the critical role of feature selection in developing accurate cancer diagnostic classifiers.

Main Methods:

Related Experiment Videos

  • Utilizing mass spectrometry (MS) for high-throughput proteomic profiling of complex biological samples.
  • Analyzing protein patterns from cancer patients and controls to build diagnostic classifiers.
  • Implementing a support vector machine-recursive feature elimination (SVM-RFE) method for feature selection.

Main Results:

  • Demonstrated the effectiveness of MS-based proteomic profiling for cancer classification.
  • Successfully applied SVM-RFE to identify significant protein biomarkers from ovarian and lung cancer datasets.
  • Highlighted the importance of feature selection in improving the accuracy of diagnostic classifiers.

Conclusions:

  • Mass spectrometry-based cancer proteomics holds significant potential for clinical diagnostics and prognostics.
  • The SVM-RFE method is a valuable tool for feature selection in MS-driven cancer classification.
  • Further development of proteomic technologies is crucial for routine clinical application in oncology.